DRL gears up for biosimilar push, consumer health growth post record FY25
Dr Reddy’s stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, biosimilar launches, and semaglutide portfolio support long-term prospects despite Revlimid taper and reduced target prices by (...)
Site référencé: The Economic Times
The Economic Times
Market caution justified after sharp rally, investors should stay vigilant : Sudip Bandyopadhyay
21/05/2025
Short-term dips seen as healthy realignments, not trend reversals : Deven Choksey
21/05/2025
Fund Manager Talk | Discretionary consumption sector set to outpace staples : Mirae’s Siddhant Chhabria
21/05/2025
Accretion Pharmaceuticals IPO listing today. Check GMP ahead of debut
21/05/2025
Borana Weaves IPO Day 2 : After strong investor response, GMP soars to 28%. Check subscription
21/05/2025
What makes Balanced Advantage Funds a superior choice for investors ?
21/05/2025
